<DOC>
	<DOCNO>NCT00561275</DOCNO>
	<brief_summary>This phase 1 study multiple peptide vaccine therapy GM-CSF treating patient esophageal cancer .</brief_summary>
	<brief_title>Safety Study Multiple Peptide Vaccine Esophageal Cancer</brief_title>
	<detailed_description>LY6K ( lymphocyte antigen 6 complex , locus K ) identify new target tumor associate antigen use cDNA microarray technology combine expression profile normal cancer tissue . On hand , anti-angiogenic therapy consider one promising approach treat cancer . In clinical trial , evaluate safety immune response multiple peptide cocktail include LY6K vascular endothelial growth factor receptor 1 ( VEGFR1 ) vascular endothelial growth factor receptor 2 ( VEGFR2 ) together IFA GM-CSF immunoadjuvants patient LY6K express primary esophageal cancer . Toxicity profile monitor , antigen specific T cell response describe .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>1 . Patients must metastatic disease esophageal cancer , treatment fail , situation effective therapy available , refuse due severe adverse effect chemotherapy 2. WHO performance status 0 2 3 . Age ≥ 20 year , ≤75 year 4 . Chemotherapy , type radiation therapy , immunotherapy within 4 week study entry 5 . Expected survival least 3 month 6 . WBC≥ 2,000/mm³ Platelet count ≥ 100,000/mm³ Total bilirubin ≤ 1.5 x institutional normal upper limit AST , ALT , ALP ≤ 2.5 x institutional normal upper limit Creatinine ≤ 1.5 x institutional normal upper limit 7 . Patients must HLAA2402 8 . Primary lesion esophageal cancer must express LY6K 9 . Able willing give valid write informed consent 1 . Pregnancy ( woman childbearing potential : Refusal inability use effective mean contraception ) 2 . Breastfeeding 3 . Serious infection require antibiotic 4 . Patient peptic ulcer disease 5 . Previous history intestinal perforation 6. bleeding disorder ( INR ≥ 1.5 ) 7 . Necessity drugmediated inhibition platelet function 8 . Taking antithrombogenic agent within 10 day 9 . Serious hypertension 10 . Previous history arterial thrombosis venous thrombosis 11 . Other malignancy within 5 year prior entry study , except treat nonmelanoma skin cancer cervical carcinoma situ 12 . Clinically significant heart disease previous history myocardial infarction within past 12 month 13 . Concomitant treatment steroid immunosuppressing agent 14 . Disease central nervous system 15 . Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>